GW Pharmaceuticals PLC (GWPH)
| Market Cap | 4.23B |
| Revenue (ttm) | 488.06M |
| Net Income (ttm) | -53.93M |
| Shares Out | 376.28M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | 243.90 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $135.73 |
| Previous Close | $137.83 |
| Change ($) | -2.10 |
| Change (%) | -1.52% |
| Day's Open | 137.90 |
| Day's Range | 134.79 - 141.50 |
| Day's Volume | 379,971 |
| 52-Week Range | 72.48 - 141.50 |
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...
GW Pharmaceuticals plc. (GWPH) CEO Justin Gover on 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)
Many marijuana stocks show promise in 2021, but these specific stocks have the best shot to build upon their strong performances last year. The post The Top 7 Marijuana Stocks to Buy for Janua...
These cannabis stocks currently have the most green.
GW Pharmaceuticals PLC provided an upbeat outlook for fourth-quarter sales, amid strength in sales of Epidiolex, the first cannabis-based drug to be approved by the Food and Drug Administratio...
Add these top growth stocks to your portfolio before it's too late.
The rapidly growing cannabis industry now has 10 companies at or above a $2 billion market cap.
LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline,...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this past week and look ahead to how the cannabis indus...
EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized
Analysts believe these pot stocks are budding with opportunity.
GW Pharmaceuticals Plc is a pharma company and a global leader in developing cannabinoid-based medicines. Its multiple sclerosis drug nabiximols (brand name Sativex) was the first natural cann...
Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.
LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts be...
- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x -
Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.
LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...
Getting exposure to the cannabis industry's upside has never been safer or cheaper.
Getting exposure to the marijuana industry has never been easier.
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...
GW Pharmaceuticals plc (GWPH) CEO Justin Gover presents at Stifel Virtual Healthcare Conference (Transcript)
During a recessionary environment is historically when VCs make a ton of money.
CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.
- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis
Company saw a surprise upside in revenues and earnings for the latest quarter. Strong pipeline means a continued revenue stream into the future.
LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercializ...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to...
With the fourth quarter almost half over, and most of the third-quarter earnings reports long since posted, most on Wall Street are reasonably satisfied with the results.
GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long...
Election 2020: What cannabis legalization means for investors and the cannabis sector
Vivien Azer Cowen Managing Director and Senior Research Analyst discusses the election day and the impact of cannabis legalization on stocks. #cannabis #marijuana #cannabislegalization Subscri...
GW Pharmaceuticals is an "underappreciated story," an analyst said as GWPH stock jumped higher on Wednesday for the second day running on better-than-expected third-quarter revenue. The post C...
GW Pharmaceuticals (GWPH) news for Wednesday includes GWPH stock continuing to rise after the release of its Q3 earnings report yesterday. The post GW Pharmaceuticals News: Why GWPH Stock Is R...
GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript
Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabin...
The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.
Momentum for Epidiolex remains very strong.
Shares of GW Pharmaceuticals PLC rallied 4.7% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform reported a narrowe...
Shares of GW Pharmaceuticals PLC were indicated up more than 6% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform ...
- Total revenue increased 51 percent to $ 137.1 million – - Epidiolex for seizures associated with TSC launch ed in the U.S. - - Nabiximols Phase 3 program in MS spasticity now recruiting - -...
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of ca...
Investors keep waiting for marijuana stocks to come to life. In 2020, the Prime Alternative Harvest Index, which covers many of the major global cannabis companies, hasn't been good.
GW Pharmaceuticals (GWPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution.
LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and ...
-- Technology p rovide s a n ew w ay for the community to c ommunicate and c onnect -- -- Launching in collaboration with patient advocacy organizations, this web-based, i mage-recognition t e...
Marijuana stocks typically have high levels of risk for investors, but these three stocks deserve to be on your radar. The post 3 Marijuana Stocks to Buy With Decriminalization on the Table ap...
Cannabis stocks surge on legalization hopes — Here's why
Vivien Azer, Cowen and Company, joins 'Power Lunch' to discuss the surge in cannabis stocks as investors anticipate legalization if there is a Biden presidency.
Investing in marijuana is speculative, but, with these marijuana ETFs you can get in on the cannabis investing game and reduce risk. The post The 5 Best Marijuana ETFs for Conservative Portfol...
About GWPH
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops vari... [Read more...]
| Industry Drug Manufacturers-General | IPO Date May 1, 2013 |
| CEO Justin Gover | Employees 901 |
| Stock Exchange NASDAQ | Ticker Symbol GWPH |
Financial Performance
In 2019, GWPH's revenue was $311.33 million, an increase of 2,344.31% compared to the previous year's $12.74 million. Losses were -$9.02 million, -96.94% less than in 2018.
Analyst Forecasts
According to 17 analysts, the average rating for GWPH stock is "Buy." The 12-month stock price forecast is 182.50, which is an increase of 34.46% from the latest price.